

A model of metastatic growth under angiogenic control.

Sébastien Benzekry

LATP, University of Provence.
Pharmacokinetic Laboratory UMR MD3.
Marseille

PhD directed by D. Barbolosi, A. Benabdallah et F. Hubert.

CANUM. June 2, 2010

Outline

1 Modeling

- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results

- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

1 Modeling


- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results

- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations


Metastases




Contrast-enhanced X-ray computed tomographies (CT) of the liver with multiple metastatic tumors. Interval : 127 days. Image from [Iwata et al., 2000](#)

+ some of the metastases are **not visible**.


Existing model. Iwata et al., 2000. Barbolosi, Benabdallah, Hubert, Verga, 2009.




Existing model. Iwata et al., 2000. Barbolosi, Benabdallah, Hubert, Verga, 2009.



Existing model. Iwata et al., 2000. Barbolosi, Benabdallah, Hubert, Verga, 2009.




Existing model. Iwata et al., 2000. Barbolosi, Benabdallah, Hubert, Verga, 2009.



$\rho(t, x) =$ density of metastases of size x at time t .

$$\begin{cases} \partial_t \rho + \partial_x(g\rho) = 0 \\ g(1)\rho(t, 1) = \int \beta(x)\rho(t, x)dx + \beta(x_p(t)) \\ \rho(0) = \rho^0 \end{cases}$$

Angiogenesis



Objectives of the model

- Predict the evolution of the number of **metastases**, especially the ones **not visible** with medical imaging (size $\leq 10^8$ cells), by taking into account the **angiogenic process**.
- Take into account the effect of cytotoxic and **cytostatic** drugs in order to **optimize the temporal administration protocols**.
- The model is based on the conjugation of two existing models : **Folkman et al., Cancer research 1999** and **Iwata et al., Journal of theoretical biology 2000**.

1 Modeling

- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results

- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

ODE model of tumoral growth under angiogenic control (Folkman, 1999)


ODE model of tumoral growth under angiogenic control

Folkman et al., Cancer Research 1999

Gompertzian growth

x = Size of the tumor

$$\frac{dx}{dt} = ax \ln \left(\frac{\theta}{x} \right)$$




ODE model of tumoral growth under angiogenic control (Folkman, 1999)

ODE model of tumoral growth under angiogenic control

Folkman et al., Cancer Research 1999


Gompertzian growth x = Size of the tumor

$$\frac{dx}{dt} = ax \ln \left(\frac{\theta}{x} \right)$$




Consider θ as a **variable** :
the angiogenic capacity

$$\frac{d\theta}{dt} = \underbrace{cx}_{\text{Stimulation by the tumor}} - \underbrace{\frac{dx^2}{3}\theta}_{\text{Inhibition}}$$



ODE model of tumoral growth under angiogenic control (Folkman, 1999)

Phase plan of the system



$$\Omega = \left[1, \left(\frac{c}{d} \right)^{\frac{3}{2}} \right]^2$$

$$G(x, \theta) = \begin{pmatrix} ax \ln \left(\frac{\theta}{x} \right) \\ cx - d\theta x^{\frac{3}{2}} \end{pmatrix}$$

$$\frac{dx}{dt} = G(X)$$

Convergence to an equilibrium point $X^* = \left(\left(\frac{c}{d} \right)^{\frac{3}{2}}, \left(\frac{c}{d} \right)^{\frac{3}{2}} \right)$. Studied in **d'Onofrio** **Gandolfi, 2004**.

1 Modeling

- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results

- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

Equation for the metastases

Primitive tumor and metastases follow the previous ODE model.

Population of the metastases structured in **size x and angiogenic capacity θ** :
 $\rho(t, x, \theta) \in L^1(\Omega)$. Balance law :

$$\partial_t \rho + \operatorname{div}(\rho G) = 0$$

Equation for the metastases

Primitive tumor and metastases follow the previous ODE model.

Population of the metastases structured in **size x and angiogenic capacity θ** :
 $\rho(t, x, \theta) \in L^1(\Omega)$. Balance law :

$$\partial_t \rho + \operatorname{div}(\rho G) = 0$$

Birth rate of new metastases of parameter σ per meta of size x and angiogenic capacity θ per unit of time :


$$B(\sigma, x, \theta) = N(\sigma)\beta(x, \theta), \quad \sigma \in \partial\Omega$$

We choose :

$$N(\sigma) = \frac{1}{2\Delta\sigma} \mathbf{1}_{\sigma \in [\sigma_0 - \Delta\sigma, \sigma_0 + \Delta\sigma]}, \quad \beta(x, \theta) = mx^\alpha$$

Two sources of new metastases :

- Primitive tumor $X_p(t)$ with $\frac{dX_p}{dt} = G(X_p)$: $N(\sigma)\beta(X_p(t)) = f(t, \sigma)$
- Metastases themselves : $N(\sigma) \int_{\Omega} \beta(x, \theta) \rho(t, x, \theta) dx d\theta$



Equation

$$\begin{cases} \partial_t \rho + \operatorname{div}(G\rho) = 0 & \Omega \\ -G \cdot \vec{\nu} \rho(t, \sigma) = N(\sigma) \int_{\Omega} \beta \rho(t, x, \theta) dx d\theta + f(t, \sigma) & \partial\Omega \\ \rho(0) = \rho^0 & \Omega \end{cases}$$

Equation

$$\begin{cases} \partial_t \rho + \operatorname{div}(\mathbf{G}\rho) = 0 & \Omega \\ -\mathbf{G} \cdot \vec{\nu} \rho(t, \sigma) = N(\sigma) \int_{\Omega} \beta \rho(t, x, \theta) dx d\theta + f(t, \sigma) & \partial\Omega \\ \rho(0) = \rho^0 & \Omega \end{cases}$$

- Linear transport equation in **dimension 2**, with **vanishing velocity field**.

Equation

$$\begin{cases} \partial_t \rho + \operatorname{div}(G\rho) = 0 & \Omega \\ -G \cdot \vec{\nu} \rho(t, \sigma) = \mathbf{N}(\sigma) \int \beta \rho(\mathbf{t}, \mathbf{x}, \theta) d\mathbf{x} d\theta + f(t, \sigma) & \partial\Omega \\ \rho(0) = \rho^0 & \Omega \end{cases}$$

- Linear transport equation in **dimension 2**, with vanishing velocity field.
- **Nonlocal boundary condition** + Source term

1 Modeling

- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results

- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

Existence, uniqueness and regularity

Benzekry, 2009

$$W_{\text{div}}(\Omega) := \{ V \in L^1(\Omega) \mid \text{div}(GV) \in L^1(\Omega) \}$$

$$D(A) = \left\{ V \in W_{\text{div}}; -G \cdot \vec{\nu} V|_{\Gamma}(\sigma) = N(\sigma) \int_{\Omega} \beta V \right\}$$

Theorem

- For $\rho^0 \in L^1(\Omega)$ and $f \in L^1([0, \infty[\times \Gamma)$, there is a **unique weak solution** and

$$\rho \in \mathcal{C}([0, \infty[; L^1(\Omega)).$$

- For $\rho^0 \in D(A)$ and $f \in \mathcal{C}^1([0, \infty[; L^1(\Gamma))$, with $f(0) = 0$,

$$\rho \in \mathcal{C}^1([0, \infty[; L^1(\Omega)) \cap \mathcal{C}([0, \infty[; W_{\text{div}}(\Omega)).$$

Existence, uniqueness, regularity and asymptotic behavior.

Asymptotic behavior

Benzekry, 2009

Theorem

Let $(\lambda_0, V, \Psi) \in \mathbb{R}^+ \times D(A) \times D(A^*)$ solving $AV = \lambda_0 V$, $A^* \Psi = \lambda_0$ (+ normalization conditions). Then,

$$\int_{\Omega} |\rho(t, x, \theta) - m(t)V(x, \theta)| \Psi(x, \theta) dx d\theta \xrightarrow[t \rightarrow +\infty]{} 0$$

$$m(t) = e^{-\lambda_0 t} \int_{\Omega} \rho(t) \Psi = \int_{\Omega} \rho^0 \Psi + \int_0^t e^{-\lambda_0 s} \int_{\partial\Omega} f(s, \sigma) \Psi(\sigma) d\sigma ds.$$

- We also have :

$$\frac{e^{\lambda_0 t} - 1}{b^\alpha} \leq \int_{\Omega} \rho(t, x, \theta) dx d\theta \leq b^\alpha e^{\lambda_0 t}$$

1 Modeling

- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results


- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

Straightening up the characteristics.

- Classical upwind scheme is **not stable**.
- Scheme based on **integration along the characteristics**.
- Change of variables :

$$\begin{array}{c} \partial_\tau \Phi = G(\Phi) \\ \Phi(0) = \sigma \end{array} \quad \left| \quad \begin{array}{ccc} \Phi : &]0, \infty[\times \Gamma^* & \rightarrow \Omega \\ & (\tau, \sigma) & \mapsto \Phi_\tau(\sigma) \end{array} \right.$$



Scheme

Benzekry, 2010

At the continuous level :

$$J(\tau, \sigma) := \text{Jac}(\Phi) = -G \cdot \vec{\nu}(\sigma) e^{\int_0^\tau \text{div}(G(\Phi_s(\sigma))) ds}$$

$$\begin{aligned}\bar{\rho}(t, \tau, \sigma) &:= \rho(t, \Phi_\tau(\sigma)) \Rightarrow \partial_t(\bar{\rho}J) + \partial_\tau(\bar{\rho}J) = 0 \\ &\Rightarrow (\bar{\rho}J)(t+s, \tau+s, \sigma) = (\bar{\rho}J)(t, \tau, \sigma)\end{aligned}$$

Scheme

Benzekry, 2010

At the continuous level :

$$J(\tau, \sigma) := \text{Jac}(\Phi) = -G \cdot \vec{\nu}(\sigma) e^{\int_0^\tau \text{div}(G(\Phi_s(\sigma))) ds}$$

$$\begin{aligned} \bar{\rho}(t, \tau, \sigma) &:= \rho(t, \Phi_\tau(\sigma)) \Rightarrow \partial_t(\bar{\rho}J) + \partial_\tau(\bar{\rho}J) = 0 \\ &\Rightarrow (\bar{\rho}J)(t+s, \tau+s, \sigma) = (\bar{\rho}J)(t, \tau, \sigma) \end{aligned}$$

$$J_h(i, j) \simeq J(\tau_i, \sigma_j), \quad \rho_h^k(i, j) \simeq \bar{\rho}(t_k, \tau_i, \sigma_j)$$

$$\left\{ \begin{array}{l} \rho^0(i, j) = 0, \quad \forall i, j \\ \rho_h^{k+1}(i+1, j) = \rho_h^k(i, j) \frac{J_h(i, j)}{J_h(i+1, j)}, \quad \forall j, 1 \leq i \leq k \\ \rho_h^{k+1}(1, j) = \frac{N(\sigma_j)}{-G(t, \sigma_j) \cdot \vec{\nu}(\sigma_j)} \{ T_{q_2}(k+1, \beta_h^{k+1} \rho_h^{k+1}) + \beta_h^{k+1}(k+1, j_0) \}, \quad \forall j \end{array} \right.$$

with

$$T_{q_2}(k, \beta^k, \rho^k) := \sum_{i,j} \beta(\Phi_{\tau_i}(\sigma_j)) \rho^k(i, j) J_h(i, j) \simeq \int_{\Omega} \beta(x, \theta) \rho(t_k, x, \theta) dx d\theta$$

Error estimate

Benzekry, 2010

Piecewise constant functions on $V(i,j) := \{\Phi_\tau(\sigma); \tau_i \leq \tau \leq \tau_{i+1}, \sigma_j \leq \sigma \leq \sigma_{j+1}\}$

$$\rho_\tau^k(X) = \rho_h^k(i,j), \quad \mathbb{P}\rho(t_k, \cdot) = \rho(t_k, \Phi_{\tau_i}(\sigma_j)) \text{ if } X \in V(i,j).$$

$$\|\varepsilon^k\|_1 := \|\rho_\tau^k - \mathbb{P}\rho(t_k)\|_{L^1}$$

- Numerical resolution of the ODE system of order α_c
- Quadrature method for the 1D integral in J of order α_1

Theorem

We assume that $\alpha_c, \alpha_1 \geq 2$, $\rho \in \mathcal{C}^1(\Omega_{t_k})$ and $\beta \in \mathcal{C}^1(\Omega)$. Then there exists a constant C such that for δt and $\delta\sigma$ small enough

$$\|\varepsilon^k\|_1 \leq C(\delta t + \delta\sigma)$$

1 Modeling

- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results

- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

Limit 2D-1D

- Problem : high computational cost (2D). **How to improve it?**


Limit 2D-1D

- Problem : high computational cost (2D). **How to improve it?**

Idea : assume that new metastases are born with a vasculature very close to a value σ_0 .

$$N(\sigma) = N^\varepsilon(\sigma) = \frac{1}{2\varepsilon} \mathbf{1}_{\sigma \in [\sigma_0 - \varepsilon, \sigma_0 + \varepsilon]} \xrightarrow[\varepsilon \rightarrow 0]{} \delta_{\sigma=\sigma_0}$$

$$\begin{cases} \partial_t \rho^\varepsilon + \operatorname{div}(\rho^\varepsilon G) = 0 \\ -G \cdot \nu(\sigma) \rho^\varepsilon(t, \sigma) = N^\varepsilon(\sigma) \left\{ \int_\Omega \beta \rho^\varepsilon(t) + f(t) \right\} \\ \rho^\varepsilon(0) = 0 \end{cases}$$



Theorem (Benzekry, 2010)

We have

$$\rho^\varepsilon(t) \rightharpoonup d\rho(t) \in \mathcal{C}([0, T]; (\mathcal{C}_b)'),$$

with convergence in $\mathcal{C}([0, T]; * - (\mathcal{C}_b)')$ for all $T > 0$. The expression of $d\rho(t)$ is given by : $\forall \psi \in \mathcal{C}_b(\Omega)$

$$\langle d\rho(t), \psi \rangle = \int_0^\infty \psi(\Phi_\tau(\sigma_0)) n(t, \tau) d\tau$$


with n solving the 1D problem

$$(E1D) \quad \begin{cases} \partial_t n + \partial_\tau n = 0 \\ n(t, 0) = \int_0^\infty \beta(\Phi_\tau(\sigma_0)) n(t, \tau) d\tau + f(t), \quad n(0, \tau) = 0 \end{cases} .$$

The measure $d\rho(t)$ solves the following problem :

$$\begin{cases} \partial_t d\rho + \operatorname{div}(d\rho G) = 0 \\ -G \cdot \nu(\sigma) d\rho(t, \sigma) = \delta_{\sigma=\sigma_0} \left\{ \int_\Omega \beta d\rho(t) + f(t) \right\}, \quad d\rho(0) = 0 \end{cases} .$$


Numerical illustration



Relative difference between the 1D problem and the 2D one VS ε .

⇒ Improvement of the computational time :

	2D	1D
$T = 5, dt = 0.1$	5.8	4.7
$T = 5, dt = 0.01$	333	35
$T = 20, dt = 0.01$	5331	519



Comparison between the 2D problem with $\varepsilon = 0.1$ and the 1D problem.

Computation times in seconds on a personal computer.

1 Modeling


- Introduction
- ODE model of tumoral growth under angiogenic control (Folkman, 1999)
- PDE model for the metastasis density

2 Theoretical results


- Existence, uniqueness, regularity and asymptotic behavior.
- Numerical scheme
- Limit 2D-1D

3 Simulations

Without treatment. Primary tumor VS Metastases.




Number of metastases until time $T = 30$ days.



Number of metastases until time $T = 50$ days






Without treatment. Visible VS not visible.



With anti-angiogenic treatment

$$G_2(t, x, \theta) = cx - d\theta x^{\frac{2}{3}} - e\gamma(t)$$

Testing various drugs :



Metastatic evolution

Primary tumor growth

Conclusion and perspectives

- Construction of a **simple model** (5 parameters) for the metastatic process.
- Theoretical study of the equation.
- Efficient numerical scheme.

Conclusion and perspectives

- Construction of a **simple model** (5 parameters) for the metastatic process.
- Theoretical study of the equation.
- Efficient numerical scheme.

Perspectives :

- **Validation** of the model by comparison with mice experiments.
- Use the model to test *in silico* various **administration protocols** for the drugs. Combination of cytotoxic/anti-angiogenic drugs. Integrate more complex PK's, interface model and toxicities control.
- Address and solve the **inverse problem**. Parameters identification.

Thank you for your attention!

Weak solutions

Definition

For $\rho^0 \in L^1(\Omega)$ and $f \in L^1(]0, \infty[\times \partial\Omega)$, a **weak solution** of the equation is a function $\rho \in \mathcal{C}([0, \infty[; L^1(\Omega))$ such that : for all $T > 0$ and all $\psi \in \mathcal{C}_c^1([0, T[\times \overline{\Omega}^*)$

$$\begin{aligned} & \int_0^T \int_{\Omega} \rho [\partial_t \psi + G \cdot \nabla \psi] + \int_{\Omega} \rho^0(\cdot) \psi(0, \cdot) - \int_{\Omega} \rho(T, \cdot) \psi(T, \cdot) \\ & - \int_0^T \int_{\partial\Omega} N(\sigma) \int_{\Omega} \beta(x, \theta) \rho(t, x, \theta) dx d\theta \psi(t, \sigma) d\sigma dt = 0 \end{aligned}$$

Weak solutions

Definition

For $\rho^0 \in L^1(\Omega)$ and $f \in L^1([0, \infty[\times \partial\Omega)$, a **weak solution** of the equation is a function $\rho \in \mathcal{C}([0, \infty[; L^1(\Omega))$ such that : for all $T > 0$ and all $\psi \in \mathcal{C}_c^1([0, T[\times \overline{\Omega}^*)$

$$\int_0^T \int_{\Omega} \rho [\partial_t \psi + G \cdot \nabla \psi] + \int_{\Omega} \rho^0(\cdot) \psi(0, \cdot) - \int_{\Omega} \rho(T, \cdot) \psi(T, \cdot) \\ - \int_0^T \int_{\partial\Omega} N(\sigma) \int_{\Omega} \beta(x, \theta) \rho(t, x, \theta) dx d\theta \psi(t, \sigma) d\sigma dt = 0$$

- For regular solutions define the **domain** of the operator $A : V \mapsto -\operatorname{div}(GV)$:


$$D(A) = \left\{ V \in W_{\operatorname{div}} ; -G \cdot \vec{\nu} V|_{\partial\Omega}(\sigma) = N(\sigma) \int_{\Omega} \beta V \right\}$$

- Assumptions on the data

$$\beta \in L^\infty, \beta \geq 0 \text{ pp}, N \in \operatorname{Lip}_c(\partial\Omega^*), N \geq 0, \int_{\partial\Omega} N = 1$$

Time evolution of the density

Numerical illustration of the asymptotic behavior




Number of metastases (log scale).

$$\lambda_0 = 0.10682$$

Spectral equation :

$$\int_0^\infty \int_\Gamma \beta(\Phi_\tau(\sigma)) e^{-\lambda_0 \tau} = 0.9909$$

Numerical illustration of the asymptotic behavior




$$\lambda_0 = 0.10682$$


Spectral equation :

$$\int_0^\infty \int_\Gamma \beta(\Phi_\tau(\sigma)) e^{-\lambda_0 \tau} = 0.9909$$

Number of metastases (log scale).



Asymptotic distribution of the density
(projection in x).



Direct eigenvector times $e^{\lambda_0 T}$
(projection in x).

Spectral problem

Find

Benzekry, 2009

$$\left\{ \begin{array}{l} (\lambda, V, \Psi) \in \mathbb{R}_+^* \times D(A) \times D(A^*) \\ AV = \lambda V, \quad A^* \Psi = \lambda \Psi \\ \int_{\Omega} V \Psi dx d\theta = 1, \quad \int_{\partial\Omega} \Psi N = 1, \quad \Psi \geq 0 \end{array} \right.$$

Proposition

Under the assumption $\int_0^\infty \int_{\partial\Omega} \beta(\Phi_\tau(\sigma)) N(\sigma) d\tau d\sigma > 1$, there is a **unique solution** (λ_0, V, Ψ) . The principal eigenvalue λ_0 solves

$$\int_0^{+\infty} \int_{\partial\Omega} \beta(\Phi_\tau(\sigma)) N(\sigma) e^{-\lambda_0 \tau} d\tau d\sigma = 1$$

The eigenvectors are given by

$$V(\Phi_\tau(\sigma)) = C_{\lambda_0} N(\sigma) e^{-\lambda_0 \tau} |J_\Phi|^{-1}, \quad \Psi(\Phi_\tau(\sigma)) = e^{\lambda_0 \tau} \int_\tau^\infty \beta(\Phi_s(\sigma)) e^{-\lambda_0 s} ds$$